Abstract

3,6-Dimethyl-1-phenyl-1H-pyrazolo[3,4-d][1,3]oxazin-4-one (3) was prepared by hydrolysis of ethyl 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (1) to afford the corresponding carboxylic acid 2, which was reacted with acetic anhydride to give 3. The pyrazolo[3,4-d][1,3]oxazin-4-one 3 was reacted with hydroxylamine hydrochloride, urea, thiourea, thiosemicarbazide, phenylhydrazine and aromatic amines to afford the corresponding pyrazolo[3,4-d]pyrimidin-4-ones 4, 5a,b, 6, 7, 8a–e, respectively. Condensation of pyrazoloxazine derivative 3 with 99% hydrazine hydrate afforded the 5-aminopyrazolo[3,4-d]pyrimidine derivative 9. Coupling of 9 with aromatic aldehydes yielded a series of 3,6-dimethyl-5-(4-substitutedbenzylideneamino)-1-phenyl-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones 10a–e. The new compounds were tested for their antitumor activity on the MCF-7 human breast adenocarcinoma cell line. Almost all the tested compounds revealed antitumor activity, especially 3,6-dimethyl-5-(4-nitrobenzylideneamino)-1-phenyl-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one (10e) which displayed the most potent inhibitory activity with a half maximal inhibitory concentration (IC50) of 11 µM.

Highlights

  • Cancer remains one of the most life-threatening diseases, taking nearly 7 million lives each year worldwide

  • It is realized that neither surgery nor radiation nor the two in combination can adequately control metastatic cancer [1], efforts to cure cancer have been focusing on conventional chemotherapy

  • This type of treatment usually does not discriminate between dividing normal cells and tumor cells, leading to severe side effects [2]

Read more

Summary

Introduction

Cancer remains one of the most life-threatening diseases, taking nearly 7 million lives each year worldwide. It is realized that neither surgery nor radiation nor the two in combination can adequately control metastatic cancer [1], efforts to cure cancer have been focusing on conventional chemotherapy. This type of treatment usually does not discriminate between dividing normal cells and tumor cells, leading to severe side effects [2]. The use of molecular targeted therapies (a new generation of selective cancer drugs which interfere with specific receptors and signaling pathways that promote tumor cell growth) has made treatments more tumor-specific [3]. Many 5-substituted-1-phenyl-1Hpyrazolo[3,4-d]pyrimidin-4-ones were reported to possess antiproliferative activity against breast carcinoma, MCF7 [14,15]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call